Menu

News & Insights

  • Clear

AG Multistate 23andMe Settlement

Connecticut AG William Tong announced a multistate settlement has been reached with the bankruptcy trustee for genetic testing company 23andMe, resolving allegations stemming from a 2023 data breach alleged to have compromised the genetic data of 6.9 million customers worldwide, including in some cases genetic ancestry information. The settlement includes $150 million in allowed claims…

Read More

AGs Target Online Child Safety Risks

State AGs continued to press online platforms and federal policymakers over youth online safety, with Texas suing Discord, Connecticut investigating Roblox, and a bipartisan AG coalition opposing federal legislation they say would undercut state authority to police online harms to minors. Texas AG Ken Paxton sued Discord under the Texas Deceptive Trade Practices Act, alleging…

Read More

Connecticut AI and Youth Social Media Bill Heads to Governor

Connecticut AG William Tong praised the state General Assembly’s passage of Senate Bill 5, which was proposed in part by his office and Governor Ned Lamont to curb addictive social media features for minors and strengthen state oversight of AI-related harms. The bill, which awaits the governor’s signature, would require parental consent before platforms expose…

Read More

CT Scores Consumer Protection Wins in Cox-Charter Merger Settlement

Connecticut AG William Tong and the Connecticut Office of Consumer Counsel entered into a proposed settlement with Charter, Cox Communications, and Cox Enterprises in connection with Charter’s change-of-control application before the Connecticut Public Utilities Regulatory Authority as a result of Charter’s acquisition of Cox operations in the state.

Read More

AG Coalition Reaches $17.85M Settlement in Generic Drug Pricing Antitrust Litigation

A coalition of 48 AGs led by Connecticut AG William Tong reached separate settlements with Lannett Company, Inc. (“Lannett”) and Bausch Health US, LLC/Bausch Health Americas, Inc. (“Bausch”) in generic-drug antitrust litigation. The states allege the companies participated in long-running conspiracies to fix prices and otherwise restrain competition in the generic drug market, including through…

Read More